Skip to Content
Merck
  • Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.

Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.

Pharmaceutical biology (2011-12-06)
M R Yadav, H P Gandhi, P P Naik, R Giridhar
ABSTRACT

The problem of hypertension has gained enormous proportions in the past decade. Multifactorial etiology and complex pathophysiology of the disease has rendered the treatment of the disease a hard task. Sympathetic nervous system and the renin-angiotensin-aldosterone system are primary contributors of blood pressure homeostasis. Structural similarities were identified among AT(1) and α(1)-antagonists, initiating a speculation that α(1)-antagonists could possibly block the AT(1) receptor and vice-versa. To corroborate this speculation, we screened prototypical α(1)-antagonists such as prazosin, doxazosin, and terazosin for antagonism of angiotensin II on rat aortic strips. We also examined the AT(1) antagonists losartan, valsartan, and olmesartan for their possible antagonistic effect, on contractions of rat aortic strips induced by phenylephrine. To our astonishment, we found that prazosin and its analogs which have been reported to have α(1)-antagonistic activity only, were able to shift concentration response curves of angiotensin II. Our findings suggest that the potent antihypertensive effect of prazosin-type α(1)-antagonists is not purely due to α(1)-receptor blocking activity of these compounds but also due to blockade of AT(1) receptors. This finding may lead to the development of more potent dual inhibitors which would prove to be of immense value in the control of the scourge of hypertension.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Terazosin hydrochloride, ≥98% (TLC), powder
Terazosin for system suitability, CRS, European Pharmacopoeia (EP) Reference Standard
Terazosin hydrochloride dihydrate, European Pharmacopoeia (EP) Reference Standard